Other OTC - Delayed Quote • USD
Inhibitor Therapeutics, Inc. (INTI)
At close: 9:39 AM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Francis E. O'Donnell Jr., M.D. | Founder, Executive Chairman & CEO | 1.09M | -- | 1950 |
Mr. James A. McNulty CPA | Interim CFO, Treasurer & Secretary | 337.96k | -- | 1950 |
Inhibitor Therapeutics, Inc.
900 West Platt Street
Suite 200
Tampa, FL 33606-2173
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3
Description
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Corporate Governance
Inhibitor Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Mar 29, 202410-K: Periodic Financial ReportsSee Full Filing
- Dec 14, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Nov 13, 202310-Q: Periodic Financial ReportsSee Full Filing
- Oct 18, 20238-K: Corporate Changes & Voting MattersSee Full Filing
- Aug 29, 20238-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 10, 2024 - May 14, 2024
Inhibitor Therapeutics, Inc. Earnings Call